

Supplemental Table. Repeated-measures analysis of changes in iPTH, serum calcium, phosphorus, alkaline phosphatase and estimated GFR from baseline through to 52 weeks.

	Paricalcitol (n=30)	Placebo (n=30)	Overall p-value
Calcium (mmol/L) (Change from baseline)			
Week 6	+0.042 (+0.005 to +0.079)	-0.010 (-0.046 to 0.027)	<0.0001
Week 12	+0.080 (+0.043 to +0.117)	+0.007 (-0.029 to +0.044)	
Week 18	+0.062 (+0.025 to +0.098)	+0.015 (-0.022 to +0.052)	
Week 24	+0.090 (+0.054 to +0.128)	+0.002 (-0.035 to +0.039)	
Week 30	+0.126 (+0.089 to +0.163)	+0.016 (-0.020 to +0.533)	
Week 36	+0.094 (+0.057 to +0.131)	+0.015 (-0.022 to +0.052)	
Week 42	+0.128 (+0.091 to +0.165)	-0.008 (-0.045 to +0.029)	
Week 48	+0.099 (+0.062 to +0.136)	+0.010 (-0.027 to +0.047)	
Week 52	+0.068 (+0.031 to +0.104)	+0.010 (-0.026 to +0.047)	
Phosphorus (mmol/L) (Change from baseline)			
Week 6	+0.041 (-0.025 to +0.108)	-0.011 (-0.078 to +0.055)	0.07
Week 12	+0.075 (+0.009 to +0.142)	-0.010 (-0.077 to +0.056)	
Week 18	-0.061 (-0.127 to +0.006)	-0.006 (-0.072 to +0.061)	
Week 24	+0.054 (-0.012 to +0.120)	-0.005 (-0.071 to +0.062)	
Week 30	-0.027 (-0.093 to +0.039)	-0.064 (-0.130 to +0.003)	
Week 36	+0.034 (-0.032 to +0.101)	+0.025 (-0.041 to +0.092)	
Week 42	+0.012 (-0.054 to +0.079)	-0.027 (-0.094 to +0.038)	
Week 48	-0.009 (-0.076 to +0.057)	-0.027 (-0.093 to +0.039)	
Week 52	+0.048 (-0.018 to +0.115)	+0.032 (-0.035 to +0.098)	
Alkaline phosphatase (U/L) (Change from baseline)			
Week 6	-8.48 (-14.74 to -2.21)	-1.02 (-7.29 to +5.24)	<0.0001
Week 12	-13.94 (-20.21 to -7.67)	+4.34 (-1.93 to +10.61)	
Week 18	-15.68 (-21.94 to -9.41)	+2.24 (-4.03 to +8.51)	

Week 24	-15.18 (-21.44 to -8.91)	+2.34 (-3.93 to +8.61)	
Week 30	-16.81 (-23.08 to -10.54)	+3.38 (-2.89 to +9.64)	
Week 36	-17.08 (-23.34 to -10.81)	+6.24 (-0.03 to +12.51)	
Week 42	-16.64 (-22.91 to -10.37)	+2.44 (-3.83 to +8.71)	
Week 48	-15.91 (-22.18 to -9.64)	+3.31 (-2.96 to +9.58)	
Week 52	-15.61 (-21.88 to -9.34)	+3.74 (-2.53 to +10.01)	
iPTH (pg/mL) (Change from baseline)			
Week 12	-83.4 (-115.0 to -51.9)	+28.1 (-3.4 to +59.7)	<0.0001
Week 24	-98.0 (-129.5 to -66.4)	+16.7 (-14.8 to +48.3)	
Week 36	-100.8 (-132.2 to -69.2)	+27.1 (-4.4 to +58.6)	
Week 52	-100.1 (-135.6 to -64.3)	+59.8 (+28.3 to +91.3)	
Estimated GFR (ml/min per 1.73m ²)			
(Change from baseline)			
Week 6	-1.59 (-3.61 to +0.42)	-1.78 (-3.79 to +0.23)	0.002
Week 12	-2.05 (-4.06 to -0.03)	-1.33 (-3.34 to +0.68)	
Week 18	-4.58 (-6.59 to -2.56)	-3.23 (-5.25 to -1.22)	
Week 24	-3.74 (-5.76 to -1.73)	-0.81 (-2.82 to +1.20)	
Week 30	-4.55 (-6.56 to -2.53)	-2.63 (-4.64 to -0.61)	
Week 36	-4.49 (-6.50 to -2.47)	-1.98 (-4.00 to +0.03)	
Week 42	-4.65 (-6.67 to -2.64)	-2.63 (-4.64 to -0.61)	
Week 48	-4.15 (-6.17 to -2.14)	-3.27 (-5.28 to -1.25)	
Week 52	-4.49 (-6.51 to -2.48)	-3.03 (-5.04 to -1.01)	
Serum urea (mmol/L) (Change from baseline)			
Week 6	+2.23 (-0.30 to +4.76)	+1.54 (-0.99 to +4.07)	0.8
Week 12	+2.38 (-0.15 to +4.91)	+1.04 (-1.49 to +3.56)	
Week 18	+2.56 (+0.03 to +5.09)	+3.14 (+0.61 to +5.67)	
Week 24	+1.81 (-0.72 to +4.34)	+1.24 (-1.28 to +3.77)	
Week 30	+2.64 (+0.11 to +5.16)	+2.25 (-0.28 to +4.78)	
Week 36	+2.07 (-0.46 to +4.60)	+5.98 (+3.45 to +8.50)	
Week 42	+3.24 (+0.71 to +5.77)	+3.75 (+1.22 to +6.28)	

Week 48	+2.96 (+0.43 to +5.48)	+2.95 (+0.42 to +5.48)	
Week 52	+3.77 (+1.24 to +6.29)	+3.23 (+0.70 to +5.76)	
<hr/>			
24-hour urine protein (g/day)(Change from baseline)			
Week 24	-0.19 (-0.51 to +0.12)	-0.02 (-0.33 to +0.30)	0.6
Week 52	-0.17 (-0.49 to +0.14)	-0.16 (-0.48 to +0.16)	
<hr/>			
Systolic blood pressure (mmHg)(Change from baseline)			
Week 6	-2.65 (-8.02 to +2.72)	-0.17 (-5.54 to +5.20)	0.03
Week 12	-1.40 (-6.77 to +3.97)	-0.03 (-5.40 to +5.34)	
Week 24	-9.05 (-14.42 to -3.68)	+3.53 (-1.84 to +8.90)	
Week 36	-5.42 (-10.79 to -0.05)	-1.95 (-7.32 to +3.42)	
Week 52	-7.47 (-12.84 to -2.10)	-7.97 (-13.34 to -2.60)	
<hr/>			
Diastolic blood pressure (mmHg)(Change from baseline)			
Week 6	-1.92 (-5.72 to +1.89)	-2.48 (-6.29 to +1.32)	0.9
Week 12	0.70 (-3.11 to +4.50)	-2.05 (-5.85 to +1.76)	
Week 24	-5.33 (-9.14 to +1.53)	-1.60 (-5.40 to +2.21)	
Week 36	-4.33 (-8.14 to -0.53)	-3.43 (-7.24 to +0.37)	
Week 52	-5.95 (-9.76 to -2.15)	-6.48 (-10.29 to -2.68)	

*Data expressed as adjusted least-squares means (95% confidence intervals). Model included terms of treatment, visit, treatment x visit interaction and baseline value.

P-value indicates test of significance between treatment groups for the overall effect (all visits combined) from the mixed-effects model.

N = 30 at all time points for all secondary analysis in both paricalcitol and placebo groups.